Trial watch adoptive cell transfer for anticancer immunotherapy

OncoImmunology

Volumn 2, Issue 5, 2013, Pages

  Vacchelli, Erika ^a,b,c   Eggermont, Alexander ^b   Fridman, Wolf Hervé ^d,e,f   Galon, Jérôme ^e,f,g,h   Tartour, Eric ^f,g,h   Zitvogel, Laurence ^b,i   Kroemer, Guido ^a,c,d,e,f   Galluzzi, Lorenzo ^a,d,e  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Institut Gustave Roussy   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g INSER M U872   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ University Paris XI   (France)

Author keywords

Chimeric antigen receptor; Cyclophosphamide; FOXP3+ regulatory T cells; Lymphodepletion; T cell receptor; Tumor infiltrating lymphocytes

Indexed keywords

LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BILE DUCT CARCINOMA; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CELL TRANSFER; CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; ESOPHAGUS CANCER; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LARGE CELL LYMPHOMA; MERKEL CELL TUMOR; MESOTHELIOMA; METASTATIC MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NASOPHARYNX CARCINOMA; NEUROBLASTOMA; NONHUMAN; OVARY CARCINOMA; PANCREAS CARCINOMA; T LYMPHOCYTE;

EID: 84885162273     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24238     Document Type: Article

References (151)

1. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat Rev Clin Oncol 2011; 8:577-85; PMID:21808266; http://dx.doi.org/10.1038/nrclinonc.2011.116
2. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012; 4:ps8; PMID:22461638; http://dx.doi.org/10.1126/scitranslmed.3003634
3. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29:4828-36; PMID:22042955; http://dx.doi.org/10.1200/JCO.2011.38.0899
4. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi. org/10.1038/nrc2355
5. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191
6. Margolin K. Ipilimumab in a Phase II trial of melanoma patients with brain metastases. Oncoimmunology 2012; 1:1197-9; PMID:23170278; http://dx.doi. org/10.4161/onci.20687
7. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1:1223-5; PMID:23243584; http://dx.doi. org/10.4161/onci.21335
8. Beyer M. Interleukin-2 treatment of tumor patients can expand regulatory T cells. Oncoimmunology 2012; 1:1181-2; PMID:23170272; http://dx.doi. org/10.4161/onci.20639
9. Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, et al. Trial Watch: Monoclonal antibodies in cancer therapy. OncoImmunology 2013; 2:e22789; http://dx.doi.org/10.4161/onci.22789
10. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès- Fridman C, Tartour E, et al. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; PMID:22720209; http://dx.doi.org/10.4161/onci.1.1.17938
11. Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, et al. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493-506; PMID:22754768; http://dx.doi.org/10.4161/onci.20459
12. Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111-34; PMID:23170259; http://dx.doi.org/10.4161/onci.21494
13. Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, et al. Trial Watch: DNA vaccines for cancer therapy. OncoImmunology 2013; 2:e23803
14. Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557-76; PMID:23264902; http://dx.doi. org/10.4161/onci.22428
15. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306-15; PMID:22737606; http://dx.doi. org/10.4161/onci.19549
16. Ueno H, Klechevsky E, Schmitt N, Ni L, Flamar AL, Zurawski S, et al. Targeting human dendritic cell subsets for improved vaccines. Semin Immunol 2011; 23:21-7; PMID:21277223; http://dx.doi. org/10.1016/j.smim.2011.01.004
17. Ueno H, Palucka AK, Banchereau J. The expanding family of dendritic cell subsets. Nat Biotechnol 2010; 28:813-5; PMID:20697407; http://dx.doi. org/10.1038/nbt0810-813
18. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010; 33:464-78; PMID:21029958; http://dx.doi.org/10.1016/j.immuni.2010.10.007
19. Jenq RR, Van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010; 10:213-21; PMID:20168320; http://dx.doi. org/10.1038/nrc2804
20. Barriga F, Ramìrez P, Wietstruck A, Rojas N. Hematopoietic stem cell transplantation: clinical use and perspectives. Biol Res 2012; 45:307-16; PMID:23283440; http://dx.doi.org/10.4067/S0716-97602012000300012
21. Bouquié R, Bonnin A, Bernardeau K, Khammari A, Dréno B, Jotereau F, et al. A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes. Cancer Immunol Immunother 2009; 58:553-66; PMID:18751701; http://dx.doi. org/10.1007/s00262-008-0578-2
22. Yun YS, Hargrove ME, Ting CC. In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 1989; 49:4770-4; PMID:2527087
23. Merhavi-Shoham E, Haga-Friedman A, Cohen CJ. Genetically modulating T-cell function to target cancer. Semin Cancer Biol 2012; 22:14-22; PMID:22210183; http://dx.doi.org/10.1016/j.semcancer.2011.12.006
24. Liu K, Rosenberg SA. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol 2001; 167:6356-65; PMID:11714800
25. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005; 175:7046-52; PMID:16272366
26. Kalbasi A, Shrimali RK, Chinnasamy D, Rosenberg SA. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J Immunother 2010; 33:672-83; PMID:20664359; http://dx.doi.org/10.1097/CJI.0b013e3181e475cd
27. Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011; 117:808-14; PMID:20971955; http://dx.doi. org/10.1182/blood-2010-05-286286
28. Bellone M, Calcinotto A, Corti A. Won't you come on in? How to favor lymphocyte infiltration in tumors. Oncoimmunology 2012; 1:986-8; PMID:23162781; http://dx.doi.org/10.4161/onci.20213
29. Kershaw MH, Teng MW, Smyth MJ, Darcy PK. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 2005; 5:928-40; PMID:16322746; http://dx.doi.org/10.1038/nri1729
30. Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M. How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology 2012; 1:1577-83; PMID:23264903; http://dx.doi. org/10.4161/onci.22524
31. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol 2011; 29:550-7; PMID:21663987; http://dx.doi. org/10.1016/j.tibtech.2011.04.009
32. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319:1676-80; PMID:3264384; http://dx.doi.org/10.1056/NEJM198812223192527
33. Olurinde MO, Shen CH, Drake A, Bai A, Chen J. Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent. Cell Mol Immunol 2011; 8:415-23; PMID:21666707; http://dx.doi.org/10.1038/cmi.2011.18
34. Song A, Tang X, Harms KM, Croft M. OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. J Immunol 2005; 175:3534-41; PMID:16148096
35. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
36. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 2012; 35:107-15; PMID:22306898; http://dx.doi.org/10.1097/CJI.0b013e318242169f
37. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16:348-53; PMID:20693846; http://dx.doi.org/10.1097/PPO.0b013e3181eb3358
38. Cheng G, Yu A, Malek TR. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev 2011; 241:63-76; PMID:21488890; http://dx.doi.org/10.1111/j.1600-065X.2011.01004.x
39. Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev 2011; 241:260-8; PMID:21488902; http://dx.doi. org/10.1111/j.1600-065X.2011.01018.x
40. Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, et al. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012; 119:5688-96; PMID:22555974; http://dx.doi.org/10.1182/blood-2011-10-386482
41. Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 2012; 189:5147-54; PMID:23100512; http://dx.doi. org/10.4049/jimmunol.1200274
42. Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 2012; 1:326-33; PMID:22737608; http://dx.doi.org/10.4161/onci.18852
43. Gattinoni L, Finkelstein SE, KlebanoffCA, Antony PA, Palmer DC, Spiess PJ, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202:907-12; PMID:16203864; http://dx.doi.org/10.1084/jem.20050732
44. KlebanoffCA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005; 26:111-7; PMID:15668127; http://dx.doi.org/10.1016/j. it.2004.12.003
45. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010; 33:1-7; PMID:19952961; http://dx.doi.org/10.1097/CJI.0b013e3181b88ffc
46. Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeux I, et al. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 1995; 63:205-12; PMID:7591205; http://dx.doi.org/10.1002/ijc.2910630210
47. Tartour E, Mathiot C, Fridman WH. Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 1992; 46:473-84; PMID:1306361; http://dx.doi. org/10.1016/0753-3322(92)90005-R
48. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107:2409-14; PMID:16304057; http://dx.doi.org/10.1182/blood- 2005-06-2399
49. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, et al. Regulatory T-cell responses to lowdose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011; 365:2067-77; PMID:22129253; http://dx.doi.org/10.1056/NEJMoa1105143
50. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365:2055-66; PMID:22129252; http://dx.doi. org/10.1056/NEJMoa1108188
51. Mignot G, Ullrich E, Bonmort M, Ménard C, Apetoh L, Taieb J, et al. The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J Immunol 2008; 180:6477-83; PMID:18453565
52. Ullrich E, Bonmort M, Mignot G, Jacobs B, Bosisio D, Sozzani S, et al. Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions. J Immunol 2008; 180:7887-97; PMID:18523252
53. Liu DL, Håkansson CH, Seifert J. Immunotherapy in liver tumors: II. Intratumoral injection with activated tumor-infiltrating lymphocytes, intrasplenic administration of recombinant interleukin-2 and interferon alpha causes tumor regression and lysis. Cancer Lett 1994; 85:39-46; PMID:7923100; http://dx.doi. org/10.1016/0304-3835(94)90236-4
54. Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 2010; 59:1325-34; PMID:20532883; http://dx.doi.org/10.1007/s00262-010-0860-y
55. Dings RP, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG, et al. Enhancement of T-cellmediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res 2011; 17:3134-45; PMID:21252159; http://dx.doi. org/10.1158/1078-0432.CCR-10-2443
56. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70:6171-80; PMID:20631075; http://dx.doi.org/10.1158/0008-5472.CAN-10-0153
57. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699-716; PMID:22934262; http://dx.doi.org/10.4161/onci.20696
58. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res 2007; 13:5280-9; PMID:17875756; http://dx.doi.org/10.1158/1078-0432.CCR-07-1378
59. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: FDAapproved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894-907; PMID:23162757; http://dx.doi.org/10.4161/onci.20931
60. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004; 5:508-15; PMID:15064759; http://dx.doi.org/10.1038/ni1059
61. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
62. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science. 1208347
63. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science. 1224922
64. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358:2698-703; PMID:18565862; http://dx.doi.org/10.1056/NEJMoa0800251
65. Li Q, Lao X, Pan Q, Ning N, Yet J, Xu Y, et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 2011; 17:4987-95; PMID:21690573; http://dx.doi. org/10.1158/1078-0432.CCR-11-0207
66. De Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7:411-23; PMID:15894262; http://dx.doi.org/10.1016/j. ccr.2005.04.014
67. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, et al. B regulatory cells and the tumor-promoting actions of TNF-a during squamous carcinogenesis. Proc Natl Acad Sci U S A 2011; 108:10662-7; PMID:21670304; http://dx.doi. org/10.1073/pnas.1100994108
68. Lister J, Rybka WB, Donnenberg AD, De Magalhaes- Silverman M, Pincus SM, Bloom EJ, et al. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clin Cancer Res 1995; 1:607-14; PMID:9816022
69. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011; 17:6287-97; PMID:21844012; http://dx.doi. org/10.1158/1078-0432.CCR-11-1347
70. Pegram HJ, Jackson JT, Smyth MJ, Kershaw MH, Darcy PK. Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol 2008; 181:3449-55; PMID:18714017
71. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-100; PMID:11896281; http://dx.doi.org/10.1126/science. 1068440
72. Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol 2009; 21:525-30; PMID:19717293; http://dx.doi. org/10.1016/j.coi.2009.07.015
73. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010; 16:2646-55; PMID:20406835; http://dx.doi.org/10.1158/1078-0432.CCR-10-0041
74. Donia M, Junker N, Ellebaek E, Andersen MH, Straten PT, Svane IM. Characterization and comparison of "Standard" and "Young" tumor infiltrating lymphocytes for adoptive cell therapy at a Danish Translational Research Institution. Scand J Immunol 2011; In press; PMID:21955245
75. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010; 16:6122-31; PMID:20668005; http://dx.doi. org/10.1158/1078-0432.CCR-10-1297
76. Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, et al. Trial Watch: Cardiac glycosides and cancer therapy. OncoImmunology 2013; 2:e23082; http://dx.doi.org/10.4161/onci.23082
77. Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179-88; PMID:22720239; http://dx.doi.org/10.4161/onci.1.2.19026
78. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, et al. Trial watch: Chemotherapy with immunogenic cell death inducers. OncoImmunology 2013; 2:e23510; http://dx.doi. org/10.4161/onci.23510
79. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx.doi.org/10.4161/onci.22009
80. Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, et al. Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood 2012; 119:2956-9; PMID:22289893; http://dx.doi.org/10.1182/blood-2011-09-378398
81. Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 2012; 23:444-50; PMID:22107246; http://dx.doi. org/10.1089/hum.2011.167
82. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709-20; PMID:22160384; http://dx.doi. org/10.1182/blood-2011-10-384388
83. Meij P, Jedema I, Van der Hoorn MA, Bongaerts R, Cox L, Wafelman AR, et al. Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study. Haematologica 2012; 97:1205-8; PMID:22511490; http://dx.doi. org/10.3324/haematol.2011.053371
84. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012; 119:3940-50; PMID:22308288; http://dx.doi.org/10.1182/blood- 2011-10-387969
85. Linn YC, Niam M, Chu S, Choong A, Yong HX, Heng KK, et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 2012; 47:957-66; PMID:21986635; http://dx.doi.org/10.1038/bmt.2011.202
86. Grupp SA, Prak EL, Boyer J, McDonald KR, Shusterman S, Thompson E, et al. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin Cancer Res 2012; 18:6732-41; PMID:23092876; http://dx.doi.org/10.1158/1078-0432.CCR-12-1432
87. Ellebaek E, Iversen TZ, Junker N, Donia M, Engell- Noerregaard L, Met O, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and lowdose Interleukin-2 in metastatic melanoma patients. J Transl Med 2012; 10:169; PMID:22909342; http://dx.doi.org/10.1186/1479-5876-10-169
88. Kandalaft LE, Powell DJ Jr., Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 2012; 10:157; PMID:22863016; http://dx.doi.org/10.1186/1479-5876-10-157
89. Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, et al. Effective treatment of metastatic forms of Epstein- Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 2012; 72:1116-25; PMID:22282657; http://dx.doi.org/10.1158/0008-5472.CAN-11-3399
90. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2011; 2:363-8; PMID:21716717; http://dx.doi.org/10.7150/jca.2.363
91. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
92. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012; 4:32ra53; PMID:22553251; http://dx.doi.org/10.1126/scitranslmed. 3003761
93. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human ß-thalassaemia. Nature 2010; 467:318-22; PMID:20844535; http://dx.doi.org/10.1038/nature09328
94. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118:3132-42; PMID:18688285; http://dx.doi.org/10.1172/JCI35700
95. Brimnes MK, Gang AO, Donia M, Thor Straten P, Svane IM, Hadrup SR. Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion. Cancer Immunol Immunother 2012; 61:1221-31; PMID:22237888; http://dx.doi.org/10.1007/s00262-011-1199-8
96. Rubinstein MP, Cloud CA, Garrett TE, Moore CJ, Schwartz KM, Johnson CB, et al. Ex vivo interleukin- 12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg 2012; 214:700-7, discussion 707-8; PMID:22360982; http://dx.doi.org/10.1016/j.jamcollsurg.2011.12.034
97. Hervas-Stubbs S, Mancheño U, Riezu-Boj JI, Larraga A, Ochoa MC, Alignani D, et al. CD8 T cell priming in the presence of IFN-a renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. J Immunol 2012; 189:3299-310; PMID:22925929; http://dx.doi.org/10.4049/jimmunol.1102495
98. Donia M, Hansen M, Sendrup SL, Iversen TZ, Ellebxk E, Andersen MH, et al. Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion. J Invest Dermatol 2013; 133:545-52; PMID:23014345; http://dx.doi.org/10.1038/jid.2012.336
99. Santegoets SJ, Turksma AW, Suhoski MM, Stam AG, Albelda SM, Hooijberg E, et al. IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med 2013; 11:37; PMID:23402380; http://dx.doi. org/10.1186/1479-5876-11-37
100. Montinaro A, Forte G, Sorrentino R, Luciano A, Palma G, Arra C, et al. Adoptive immunotherapy with Cl-IB-MECA-treated CD8+ T cells reduces melanoma growth in mice. PLoS One 2012; 7:e45401; PMID:23028986; http://dx.doi.org/10.1371/journal. pone.0045401
101. Zhou Q, Schneider IC, Edes I, Honegger A, Bach P, Schönfeld K, et al. T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood 2012; 120:4334-42; PMID:22898597; http://dx.doi.org/10.1182/blood-2012-02-412973
102. Lutz-Nicoladoni C, Wallner S, Stoitzner P, Pircher M, Gruber T, Wolf AM, et al. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine. Immunol Cell Biol 2012; 90:130-4; PMID:21383769; http://dx.doi.org/10.1038/icb.2011.11
103. Stromnes IM, Fowler C, Casamina CC, Georgopolos CM, McAfee MS, Schmitt TM, et al. Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo. J Immunol 2012; 189:1812-25; PMID:22798667; http://dx.doi.org/10.4049/jimmunol. 1200552
104. Kunii N, Zhao Y, Jiang S, Liu X, Scholler J, Balagopalan L, et al. Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. Hum Gene Ther 2013; 24:27-37; PMID:22998346; http://dx.doi.org/10.1089/hum.2012.130
105. Grange M, Buferne M, Verdeil G, Leserman L, Schmitt-Verhulst AM, Auphan-Anezin N. Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma. Cancer Res 2012; 72:76-87; PMID:22065720; http://dx.doi.org/10.1158/0008-5472.CAN-11-2187
106. Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, et al. A coreceptor-independent transgenic human TCR mediates anti-tumor and antiself immunity in mice. J Immunol 2012; 189:1627-38; PMID:22798675; http://dx.doi.org/10.4049/jimmunol. 1103271
107. Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012; 18:1672-83; PMID:22291136; http://dx.doi. org/10.1158/1078-0432.CCR-11-3050
108. Goldstein MJ, Kohrt HE, Houot R, Varghese B, Lin JT, Swanson E, et al. Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells. Cancer Res 2012; 72:1239-47; PMID:22232735; http://dx.doi.org/10.1158/0008-5472.CAN-11-3375
109. Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol 2003; 4:815; PMID:12942076; http://dx.doi.org/10.1038/ni0903-815
110. Brown R, Suen H, Favaloro J, Yang S, Ho PJ, Gibson J, et al. Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma. Oncoimmunology 2012; 1: 1658-60; PMID:2326492; http://dx.doi. org/10.4161/onci.22032
111. Somanchi SS, Somanchi A, Cooper LJ, Lee DA. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood 2012; 119:5164-72; PMID:22498742; http://dx.doi.org/10.1182/blood- 2011-11-389924
112. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013; 31:71-5; PMID:23242161; http://dx.doi.org/10.1038/nbt.2459
113. Morgan RA. Faster, cheaper, safer, T-cell engineering. J Immunother 2013; 36:1-2; PMID:23211627; http://dx.doi.org/10.1097/CJI.0b013e3182791257
114. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J 2010; 16:336-41; PMID:20693844; http://dx.doi.org/10.1097/PPO.0b013e3181eb3879
115. Liu C, Lewis CM, Lou Y, Xu C, Peng W, Yang Y, et al. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother 2012; 35:276-82; PMID:22421945; http://dx.doi.org/10.1097/CJI.0b013e31824e7f43
116. Noji S, Hosoi A, Takeda K, Matsushita H, Morishita Y, Seto Y, et al. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy. J Immunother 2012; 35:460-72; PMID:22735804; http://dx.doi.org/10.1097/CJI.0b013e31826092db
117. Ju SA, Park SM, Lee YS, Bae JH, Yu R, An WG, et al. Administration of 6-gingerol greatly enhances the number of tumor-infiltrating lymphocytes in murine tumors. Int J Cancer 2012; 130:2618-28; PMID:21792901; http://dx.doi.org/10.1002/ijc.26316
118. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res 2012; 72:5209-18; PMID:22915761; http://dx.doi. org/10.1158/0008-5472.CAN-12-1187
119. Koya RC, Mok S, Otte N, Blacketor KJ, Comin- Anduix B, Tumeh PC, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012; 72:3928-37; PMID:22693252; http://dx.doi.org/10.1158/0008-5472.CAN-11-2837
120. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013; 19:393-403; PMID:23204132; http://dx.doi. org/10.1158/1078-0432.CCR-12-1626
121. Abe BT, Shin DS, Mocholi E, Macian F. NFAT1 supports tumor-induced anergy of CD4(+) T cells. Cancer Res 2012; 72:4642-51; PMID:22865456; http://dx.doi.org/10.1158/0008-5472.CAN-11-3775
122. Stark FC, Gurnani K, Sad S, Krishnan L. Lack of functional selectin ligand interactions compromises long term tumor protection by CD8+ T cells. PLoS One 2012; 7:e32211; PMID:22359671; http://dx.doi. org/10.1371/journal.pone.0032211
123. André MC, Sigurdardottir D, KuttruffS, Pömmerl B, Handgretinger R, Rammensee HG, et al. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction. Int J Cancer 2012; 131:1601-10; PMID:21607945; http://dx.doi.org/10.1002/ijc.26191
124. Dong H, Franklin NA, Roberts DJ, Yagita H, Glennie MJ, Bullock TN. CD27 stimulation promotes the frequency of IL-7 receptor-expressing memory precursors and prevents IL-12-mediated loss of CD8(+) T cell memory in the absence of CD4(+) T cell help. J Immunol 2012; 188:3829-38; PMID:22422886; http://dx.doi.org/10.4049/jimmunol.1103329
125. Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, et al. The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med 2012; 4:ra120; PMID:22932225; http://dx.doi.org/10.1126/scitranslmed.3004306
126. Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, et al. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 2013; 19:106-17; PMID:23149818; http://dx.doi.org/10.1158/1078-0432.CCR-12-2143
127. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490:412-6; PMID:23051752; http://dx.doi.org/10.1038/nature11538
128. Hanagiri T, Shigematsu Y, Kuroda K, Baba T, Shiota H, Ichiki Y, et al. Antitumor activity of human γ δ T cells transducted with CD8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes. Cancer Sci 2012; 103:1414-9; PMID:22621620; http://dx.doi. org/10.1111/j.1349-7006.2012.02337.x
129. Zhao H, Xi X, Cui L, He W. CDR3dδ-grafted γ9d2T cells mediate effective antitumor reactivity. Cell Mol Immunol 2012; 9:147-54; PMID:21909128; http://dx.doi.org/10.1038/cmi.2011.28
130. Zhou J, Kang N, Cui L, Ba D, He W. Anti-γ δ TCR antibody-expanded γ δ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Cell Mol Immunol 2012; 9:34-44; PMID:21666706; http://dx.doi.org/10.1038/cmi.2011.16
131. Siegers GM. Anti-leukemia activity of human gamma delta T cells. Oncoimmunology 2012; 1:237-9; PMID:22720255; http://dx.doi.org/10.4161/onci.1.2.18231
132. Galluzzi L, Lugli E. Rejuvenated T cells attack old tumors. OncoImmunology 2013; 2:e24103; http://dx.doi.org/10.4161/onci.24103
133. Gattinoni L, KlebanoffCA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012; 12:671-84; PMID:22996603; http://dx.doi.org/10.1038/nrc3322
134. Somerville RP, Dudley ME. Bioreactors get personal. Oncoimmunology 2012; 1:1435-7; PMID:23243620; http://dx.doi.org/10.4161/onci.21206
135. Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 2013; 121:573-84; PMID:23160470; http://dx.doi.org/10.1182/blood-2012-05-431718
136. Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, et al. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest 2013; In press; PMID:23281401; http://dx.doi.org/10.1172/JCI66327
137. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17:1290-7; PMID:21926977; http://dx.doi.org/10.1038/nm.2446
138. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 2013; 12:114-26; PMID:23290140; http://dx.doi. org/10.1016/j.stem.2012.11.002
139. Haymaker C, Wu R, Bernatchez C, Radvanyi L. PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint. Oncoimmunology 2012; 1:735-8; PMID:22934265; http://dx.doi.org/10.4161/onci.20823
140. Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K, Fujii S, et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell 2013; 12:31-6; PMID:23290135; http://dx.doi.org/10.1016/j. stem.2012.12.006
141. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5:615-25; PMID:16034368; http://dx.doi.org/10.1038/nrc1669
142. HuffV. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 2011; 11:111-21; PMID:21248786; http://dx.doi.org/10.1038/nrc3002
143. Donia M, Fagone P, Nicoletti F, Andersen RS, Høgdall E, Straten PT, et al. BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 2012; 1:1476-83; PMID:23264894; http://dx.doi. org/10.4161/onci.21940
144. Wilmott JS, Scolyer RA, Long GV, Hersey P. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology 2012; 1:997-9; PMID:23189245; http://dx.doi.org/10.4161/onci.19865
145. Waitz R, Fassò M, Allison JP. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. Oncoimmunology 2012; 1:544-6; PMID:22754781; http://dx.doi.org/10.4161/onci.19442
146. Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther 2011; 19:2258-68; PMID:21915103; http://dx.doi. org/10.1038/mt.2011.167
147. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-75; PMID:19536107; http://dx.doi. org/10.1038/nrc2656
148. Liu L, Sun M, Wang Z. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors. Cancer Lett 2012; 316:1-5; PMID:22099879; http://dx.doi.org/10.1016/j.canlet. 2011.10.027
149. Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 2008; 180:4901-9; PMID:18354214
150. Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 2012; 1:458-66; PMID:22754764; http://dx.doi. org/10.4161/onci.19855
151. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy- Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365:1673-83; PMID:22047558; http://dx.doi. org/10.1056/NEJMoa1106152